Search hospitals > Delaware > Wilmington

Alfred I duPont Hospital for Children

Claim this profile
Wilmington, Delaware 19803
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Global Leader in Uterine Tumors
Conducts research for Cancer
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Brain Tumor
381 reported clinical trials
16 medical researchers
Photo of Alfred I duPont Hospital for Children in WilmingtonPhoto of Alfred I duPont Hospital for Children in WilmingtonPhoto of Alfred I duPont Hospital for Children in Wilmington

Summary

Alfred I duPont Hospital for Children is a medical facility located in Wilmington, Delaware. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Uterine Tumors, Cancer, Acute Lymphoblastic Leukemia, Brain Tumor and other specialties. Alfred I duPont Hospital for Children is involved with conducting 381 clinical trials across 666 conditions. There are 16 research doctors associated with this hospital, such as Scott M. Bradfield, Ramamoorthy Nagasubramanian, Emi H. Caywood, and Michael Bober.

Area of expertise

1T-Lymphoblastic Leukemia/Lymphoma
Global Leader
Alfred I duPont Hospital for Children has run 79 trials for T-Lymphoblastic Leukemia/Lymphoma. Some of their research focus areas include:
Stage II
Philadelphia chromosome positive
BCR-ABL1 positive
2Uterine Tumors
Global Leader
Alfred I duPont Hospital for Children has run 66 trials for Uterine Tumors. Some of their research focus areas include:
Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at Alfred I duPont Hospital for Children

Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Brain Tumor
T-Lymphoblastic Leukemia/Lymphoma
Testicular cancer
Lymphoid Leukemia
Leukemia
Acute Leukemia
Lymphoma
Uterine Tumors
Image of trial facility.

Levocarnitine

for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma

This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Image of trial facility.

Blinatumomab + Dasatinib/Imatinib

for Acute Lymphoblastic Leukemia

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib and imatinib are in a class of medications called tyrosine kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib or imatinib in combination with standard chemotherapy may work better in treating patients with Ph+ or Ph-like ABL-class B-ALL than dasatinib or imatinib with chemotherapy.
Recruiting2 awards Phase 35 criteria
Image of trial facility.

Inotuzumab Ozogamicin

for Acute Lymphoblastic Leukemia

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Alfred I duPont Hospital for Children?
Alfred I duPont Hospital for Children is a medical facility located in Wilmington, Delaware. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Uterine Tumors, Cancer, Acute Lymphoblastic Leukemia, Brain Tumor and other specialties. Alfred I duPont Hospital for Children is involved with conducting 381 clinical trials across 666 conditions. There are 16 research doctors associated with this hospital, such as Scott M. Bradfield, Ramamoorthy Nagasubramanian, Emi H. Caywood, and Michael Bober.
Where is Alfred I duPont Hospital for Children located?
**Directions to Alfred I duPont Hospital for Children:** - **From the North or South:** Take I-95 to Exit 8. Follow US 202 North to Route 141, then turn left onto Route 141. - **Address:** 1600 Rockland Road, Wilmington, DE 19803.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Alfred I duPont Hospital for Children, families can apply through Nemours Children's Health Financial Assistance Program for reduced rates or no charge care for qualifying patients. Contact Nemours Financial Services or visit Nemours.org for application details and guidelines, where financial advocates are also available to assist. For insurance inquiries, reach out to the Patient Accounts department at Dupont Hospital.
What insurance does Alfred I duPont Hospital for Children accept?
The Alfred I duPont Hospital for Children accepts various insurance plans, including Highmark Blue Cross Blue Shield of Delaware and Highmark of Pennsylvania through the BlueCard program. Horizon Blue Cross Blue Shield of New Jersey terminated its hospital contract with Nemours/Alfred I duPont Hospital for Children in 2014, making it out of network for Horizon BCBSNJ members. Nemours Children's Health accepts many types of insurance plans; however, it's crucial to check with your insurance provider regarding coverage for specific services.
What awards or recognition has Alfred I duPont Hospital for Children received?
Alfred I. duPont Hospital for Children in Wilmington, Delaware, is renowned for its research and care in chronic and rare childhood diseases. Supported by the Nemours Foundation since 1936, it has achieved Magnet status multiple times and is consistently ranked by U.S. News & World Report’s Top Children’s Hospital awards. The hospital also offers biomedical research fellowship training and undergraduate summer scholarship programs for medical students.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security